Chronic Spontaneous Urticaria&nbsp;
&nbsp;
Chronic spontaneous urticaria (CSU) or Chronic Idiopathic urticaria (CIU) is defined as persistent symptoms of urticaria for 6 weeks or more. It is a distressing skin condition that causes red, swollen, itchy, and sometimes painful hives or &ldquo;wheals&rdquo; on the skin. It is being associated with autoimmunity in almost half of the cases, but the remaining cases still remain &ldquo;idiopathic,&rdquo; and all are considered spontaneous. Therefore, the term chronic spontaneous urticaria (CSU) has been employed to indicate chronic urticaria that is endogenous and is independent of any external physical stimulus, which is conceptually helpful and does not imply knowing or not-knowing the cause.
&nbsp;
Chronic Spontaneous Urticaria Epidemiology Segmentation in the 7MM&nbsp;
&nbsp;
<ul>
<li class="ql-align-justify">Total Prevalent cases of Chronic Spontaneous Urticaria</li>
<li class="ql-align-justify">Gender-Specific cases of Chronic Spontaneous Urticaria</li>
<li class="ql-align-justify">Age-specific cases of Chronic Spontaneous Urticaria</li>
<li class="ql-align-justify">Total diagnosed and Treatable prevalent cases of Chronic Spontaneous Urticaria</li>
</ul>
&nbsp;
Chronic Spontaneous Urticaria Epidemiological Insights Observed in the 7MM (2022)
&nbsp;
<ul>
<li class="ql-align-justify">The total diagnosed prevalent population of Chronic Spontaneous Urticaria in the 7MM were found to be 4.1 million.</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market" target="_blank" rel="noopener noreferrer">Chronic Spontaneous Urticaria Market Insight</a>
&nbsp;
The market size of Chronic Spontaneous Urticaria in the 7MM was found to be USD 2 billion in 2022. &nbsp;
&nbsp;
Chronic Spontaneous Urticaria Market Drivers
&nbsp;
<ul>
<li class="ql-align-justify">Treatment side effects with currently available treatment</li>
<li class="ql-align-justify">The economic burden on patients</li>
<li class="ql-align-justify">Increase in research and development activities</li>
<li class="ql-align-justify">Increasing market size</li>
</ul>
&nbsp;
Chronic Spontaneous Urticaria Market Barriers
&nbsp;
<ul>
<li class="ql-align-justify">Lack of understanding of disease pathology</li>
<li class="ql-align-justify">Approaching patent cliff</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight" target="_blank" rel="noopener noreferrer">Chronic Spontaneous Urticaria Emerging Therapies</a>
&nbsp;
The emerging drugs in the Chronic Spontaneous Urticaria market are
<ul>
<li class="ql-align-justify">Dupilumab</li>
<li class="ql-align-justify">Ligelizumab</li>
<li class="ql-align-justify">Benralizumab</li>
<li class="ql-align-justify">Fenebrutinib</li>
<li class="ql-align-justify">KPL-716</li>
<li class="ql-align-justify">LOU064, and several others</li>
</ul>
&nbsp;
Chronic Spontaneous Urticaria Key Players&nbsp;
&nbsp;
The key players working in the Chronic Spontaneous Urticaria market are
&nbsp;
<ul>
<li class="ql-align-justify">Sanofi</li>
<li class="ql-align-justify">Regeneron</li>
<li class="ql-align-justify">Novartis Pharmaceuticals</li>
<li class="ql-align-justify">AstraZeneca</li>
<li class="ql-align-justify">Genentech, Inc.</li>
<li class="ql-align-justify">Kiniksa Pharmaceuticals, Ltd</li>
<li class="ql-align-justify">Novartis Pharmaceuticals, and many others</li>
</ul>

Chronic Spontaneous Urticaria Market

Chronic Spontaneous Urticaria Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape